Encinitas, California — December 1, 2025 — Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) covering additional and novel formulations for the KIO-100 family of anti-inflammatory compounds, significantly expanding delivery options and enhancing the therapeutic reach of its lead candidate KIO-104, a next-generation non-steroidal DHODH inhibitor for retinal inflammation. The newly issued patent strengthens the company’s intellectual property position as the ongoing Phase 2 KLARITY clinical trial continues enrolling patients for multiple inflammatory retinal conditions, reflecting strong momentum across Kiora’s developmental pipeline.

Science Significance

The issuance of this patent highlights the growing scientific relevance of DHODH inhibition as a targeted strategy to slow, halt, or reverse inflammation-driven retinal degeneration, a mechanism supported by early clinical findings for KIO-104. The novel formulation protected under this patent provides expanded delivery flexibility, allowing deeper exploration of retinal localization strategies that improve drug penetration, reduce systemic exposure, and optimize therapeutic index. The compound’s small-molecule design, paired with preclinical and Phase 1 clinical data demonstrating proof-of-concept in non-infectious uveitis, underscores KIO-104’s potential to redefine how inflammatory retinal diseases are treated, especially in cases where steroids and biologics fail to achieve adequate responses.

Regulatory Significance

From a regulatory standpoint, the new formulation patent enhances the robustness of Kiora’s intellectual-property portfolio, an essential component of long-term regulatory-commercial strategy, particularly for therapies intended for chronic ophthalmic use. The active Phase 2 KLARITY trial, designed to evaluate higher doses of KIO-104 across posterior non-infectious uveitis and diabetic macular edema, represents a key milestone in generating the efficacy and safety evidence required for future pivotal registration studies. As regulatory agencies increasingly emphasize safety for intraocular drug delivery, KIO-104’s progress as a locally delivered, non-steroidal immunomodulator positions it favorably for alignment with emerging regulatory expectations and cGxP-compliant oversight frameworks.

Business Significance

For Kiora Pharmaceuticals, this patent grant significantly strengthens the company’s competitive positioning within the ophthalmic therapeutics sector. By securing legal protection for additional formulations, Kiora gains strategic flexibility to expand into new delivery routes, differentiate its product in a crowded retinal-disease market, and support long-term lifecycle management strategies for KIO-104. The patent also increases the attractiveness of KIO-104 to potential industry collaborators, contract manufacturers, and investors, especially given the initiation of the KLARITY study, which investigates treatment options for up to 28 patients with macular edema, a condition with substantial unmet need. Together with the advancement of KIO-301—a molecular photoswitch targeting inherited retinal diseases—the strengthened IP estate enhances the company’s broader R&D pipeline valuation.

Patients’ Significance

Patients suffering from retinal diseases such as posterior non-infectious uveitis, diabetic macular edema, and chronic retinal inflammation often rely on steroids or systemic immunosuppressants, both of which carry significant safety concerns including cataract risk, elevated intraocular pressure, and systemic immunosuppression. KIO-104’s targeted DHODH-inhibition mechanism offers a promising alternative that may deliver anti-inflammatory effects without the limitations of existing therapies. The potential for local delivery, now supported by expanded formulation options, is particularly meaningful for patients who require sustained treatment without compromising long-term ocular safety. Early data showing feasibility and tolerability in Phase 1 trials amplify the therapy’s potential to reshape care standards for individuals experiencing inflammation-related vision loss.

Policy Significance

The expansion of formulation-based intellectual property for KIO-104 has notable implications for healthcare policy, particularly as regulators and payers seek sustainable solutions for chronic retinal diseases. The patent helps secure innovator protections that encourage continued investment in small-molecule ophthalmic therapeutics, supporting broader policy goals of advancing alternatives to systemic corticosteroids and costly biologics. As retinal diseases increasingly contribute to healthcare spending and disability burden, KIO-104’s progress could influence future treatment guidelines, reimbursement frameworks, and regulatory initiatives aimed at accelerating the development of non-steroidal, inflammation-modulating therapies geared toward patient safety and long-term disease control.

Kiora Pharmaceuticals’ newly granted U.S. patent marks a pivotal advancement for the KIO-100 family, reinforcing KIO-104’s scientific, regulatory, and commercial trajectory as it advances through clinical development. With expanded formulation options, strong preclinical rationale, and active enrollment in the KLARITY Phase 2 trial, Kiora is strengthening its position in the retinal-disease therapeutic landscape. The patent underscores the company’s commitment to pioneering innovative small-molecule approaches for inflammatory vision disorders and sets the stage for future clinical and regulatory milestones that could meaningfully improve treatment options for patients with chronic retinal inflammation.

Source: Kiora Pharmaceuticals, Inc. press release